De Chao Yu
Chief Executive Officer en INNOVENT BIOLOGICS, INC. .
Fortuna: 526 M $ al 31/03/2024
Perfil
Fundador de Innovent Biologics, Inc. y Chengdu Kanghong Pharmaceutical Group Co., Ltd., De Chao Yu ocupa el cargo de Presidente y Director General de Innovent Biologics, Inc. y Presidente de la Sociedad China de Anticuerpos. También forma parte del consejo de administración de Babytree Group y Cheerwin Group Ltd. y es profesor de la Universidad de Sichuan. Anteriormente, De Chao Yu fue Presidente y Director General de Chengdu Kanghong Pharmaceutical Group Co. Ltd., Vicepresidente de Investigación y Desarrollo de Applied Genetic Technologies Corp., Vicepresidente de Investigación y Desarrollo de Applied Genetics, Inc. y Presidente y Director General de Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd., Vicepresidente de Investigación y Desarrollo de Calyon North America, Inc., Vicepresidente de Calydon, Inc. y Director General de la Asociación de Biotecnología Médica de China. Se doctoró en la Academia China de Ciencias.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INNOVENT BIOLOGICS, INC.
6.73% | 22/03/2024 | 109 245 165 ( 6.73% ) | 526 M $ | 31/03/2024 |
Cargos activos de De Chao Yu
| Empresas | Cargo | Inicio |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Chief Executive Officer | 28/04/2011 |
| Sichuan University | Corporate Officer/Principal | 01/01/2008 |
| Chinese Antibody Society | Chairman | 01/01/2017 |
Antiguos cargos conocidos de De Chao Yu.
| Empresas | Cargo | Fin |
|---|---|---|
| BABYTREE GROUP | Director/Board Member | 10/05/2023 |
| CHEERWIN GROUP LIMITED | Director/Board Member | 14/10/2022 |
| China Medicinal Biotech Association | Corporate Officer/Principal | 01/01/2019 |
| PHARMABLOCK SCIENCES (NANJING), INC. | Director/Board Member | 01/01/2018 |
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Chief Executive Officer | 01/01/2011 |
Formación de De Chao Yu.
| Chinese Academy of Sciences | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Health Technology |
| INNOVENT BIOLOGICS, INC. | Health Technology |
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| BABYTREE GROUP | Commercial Services |
| CHEERWIN GROUP LIMITED | Process Industries |
| Empresas privadas | 7 |
|---|---|
Calydon, Inc.
 Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The private company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Calyon North America, Inc.
 Calyon North America, Inc. Regional BanksFinance Part of SAS Rue la Boétie, Calyon North America, Inc. is a private company based in New York, NY. | Finance |
| China Medicinal Biotech Association | |
| Applied Genetics, Inc. | |
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd.
 Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ellimist Singapore Pte Ltd., Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. is a pharmaceutical company that manufactures and supplies pharmaceutical products. The private company is based in Chengdu, China. Kanghong Sagent Chengdu Pharmaceutical Corp. was acquired by Sagent Pharmaceuticals, Inc., part of Ellimist Singapore Pte Ltd. from February 28, 2023 on June 04, 2013 for $4.06 million. The Chinese company was founded in 2006. | Health Technology |
| Chinese Antibody Society |
- Bolsa de valores
- Insiders
- De Chao Yu
